



Australian Government
Department of Health and Aged Care
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	228775	Allimax
ARTG entry for	Medicine Listed	
Sponsor	Biomedica Nutraceuticals Pty Ltd	
Postal Address	PO Box 7052, ALEXANDRIA, NSW, 2015 Australia	
ARTG Start Date	1/10/2014	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . Allimax

Product Type	Single Medicine Product	Effective Date	26/07/2019
---------------------	-------------------------	-----------------------	------------

Permitted Indications

Traditionally used in Western herbal medicine to sudorific/diaphoretic/enhance/promote sweating/perspiration

Helps in the maintenance of healthy blood lipids/blood fats

Maintain/support cardiovascular system health

Maintain/support healthy cardiovascular system function

Traditionally used in Western herbal medicine to vermifuge/helps remove intestinal threadworms/pinworms

Traditionally used in Western herbal medicine to decongestant/relieve nasal congestion

Traditionally used in Western herbal medicine to decrease/reduce/relieve mild upper respiratory tract congestion

Traditionally used in Western herbal medicine to decrease/reduce/relieve the severity of symptoms of mild upper respiratory tract infections

Traditionally used in Western herbal medicine to expectorant/clear respiratory tract mucous

Traditionally used in Western herbal medicine to relieve symptoms of mild upper respiratory tract infections

Traditionally used in Western herbal medicine to decrease/reduce/relieve symptoms of common cold

Traditionally used in Western herbal medicine to enhance/improve/promote/increase cough productivity

Indication Requirements

Product presentation must not imply or refer to serious cardiovascular conditions.

Product presentation must not imply or refer to serious forms of respiratory disorders/diseases, such as: asthma, pneumonia, COAD, COPD, influenza.

Label statement: If symptoms persist, talk to your health professional.

Label statement: Adults only, OR Not to be used in children under 2 years of age without medical advice (or words to that effect).

Product presentation must not imply or refer to lowering blood lipids, blood fats and triglycerides.

Respiratory tract infections must be qualified by 'mild'.



Australian Government
Department of Health and Aged Care
Therapeutic Goods Administration

Product presentation must not imply or refer to other worms e.g. roundworm, tapeworm, hookworm.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

No Warnings included on Record

Additional Product information

Pack Size/Poison information

Pack Size

Poison Schedule

Components

1 . Formulation 1

Dosage Form Capsule, hard

Route of Administration Oral

Visual Identification

Active Ingredients

Allium sativum bulb Extract dry 180 mg

Equivalent: Allium sativum (Fresh) 3.6 mg

Allium sativum bulb Extract dry concentrate standardised 75 mg

Equivalent: Allium sativum (Fresh) 900 mg

Other Ingredients (Excipients)

Acacia

calcium hydrogen phosphate dihydrate

colloidal anhydrous silica

dl-alpha-tocopherol

Garlic Bulb Powder

hypromellose

maltodextrin

microcrystalline cellulose

purified water

silicon dioxide

sorbitol

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary